Eikon Therapeutics (EIKN) FDA Approvals $9.65 -0.12 (-1.23%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$9.66 +0.01 (+0.16%) As of 07:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock Eikon Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Eikon Therapeutics (EIKN). Over the past two years, Eikon Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as EIK1001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. EIK1001 FDA Regulatory Events EIK1001 is a drug developed by Eikon Therapeutics for the following indication: patients with stage IV NSCLC. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Abstract - July 20,2026Abstract Drug: EIK1001Announced Date: July 20, 2026Indication: patients with stage IV NSCLCAnnouncementEikon Therapeutics, Inc. announced the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.AI SummaryEikon Therapeutics announced that seven abstracts from its clinical pipeline were accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid. The updates cover several lead programs, including EIK1001, EIK1003, EIK1004, and EIK1005, across a range of cancers. For EIK1001, the company will share Phase 2 results in stage IV non-small cell lung cancer, including data from the squamous cohort, as well as a Phase 2/3 study combining the drug with pembrolizumab and chemotherapy. EIK1003 data will include studies in metastatic prostate cancer and advanced solid tumors. EIK1004 will be presented as a first-in-human study in patients with advanced solid tumors carrying HRR mutations. EIK1005 presentations will cover its use as a monotherapy and with pembrolizumab, along with safety, tolerability, and pharmacokinetic findings. The company said the abstracts reflect progress across its pipeline, but noted that forward-looking statements should not be relied on too heavily.Read Announcement Eikon Therapeutics FDA Events - Frequently Asked Questions Has Eikon Therapeutics received FDA approval? As of now, Eikon Therapeutics (EIKN) has not received any FDA approvals for its therapy in the last two years. What drugs has Eikon Therapeutics submitted to the FDA? In the past two years, Eikon Therapeutics (EIKN) has reported FDA regulatory activity for EIK1001. What is the most recent FDA event for Eikon Therapeutics? The most recent FDA-related event for Eikon Therapeutics occurred on July 20, 2026, involving EIK1001. The update was categorized as "Abstract," with the company reporting: "Eikon Therapeutics, Inc. announced the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain." What conditions do Eikon Therapeutics' current drugs treat? Currently, Eikon Therapeutics has one therapy (EIK1001) targeting the following condition: patients with stage IV NSCLC. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Innate Pharma FDA EventsACADIA Pharmaceuticals FDA EventsBelite Bio FDA EventsDogwood Therapeutics FDA EventsDyne Therapeutics FDA EventsEikon Therapeutics FDA EventsGreenwich LifeSciences FDA EventsHarrow FDA EventsImmunome FDA EventsOncolytics Biotech FDA EventsOric Pharmaceuticals FDA EventsScholar Rock FDA EventsBiohaven FDA EventsNuvation Bio FDA Events4D Molecular Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Zai Lab FDA Events Mesoblast FDA Events Ocular Therapeutix FDA Events Nanobiotix FDA Events Syndax Pharmaceuticals FDA Events Aurinia Pharmaceuticals FDA Events Nuvation Bio FDA Events Atai Beckley FDA Events Harmony Biosciences FDA Events Amylyx Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:EIKN last updated on 7/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eikon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eikon Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Abstract - July 20,2026Abstract Drug: EIK1001Announced Date: July 20, 2026Indication: patients with stage IV NSCLCAnnouncementEikon Therapeutics, Inc. announced the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.AI SummaryEikon Therapeutics announced that seven abstracts from its clinical pipeline were accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid. The updates cover several lead programs, including EIK1001, EIK1003, EIK1004, and EIK1005, across a range of cancers. For EIK1001, the company will share Phase 2 results in stage IV non-small cell lung cancer, including data from the squamous cohort, as well as a Phase 2/3 study combining the drug with pembrolizumab and chemotherapy. EIK1003 data will include studies in metastatic prostate cancer and advanced solid tumors. EIK1004 will be presented as a first-in-human study in patients with advanced solid tumors carrying HRR mutations. EIK1005 presentations will cover its use as a monotherapy and with pembrolizumab, along with safety, tolerability, and pharmacokinetic findings. The company said the abstracts reflect progress across its pipeline, but noted that forward-looking statements should not be relied on too heavily.Read Announcement
Free EIKN Stock Alerts